Christofides EA, Puente O, Norwood P, Denham D, et al. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus(R)) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study. Diabetes Obes Metab 2024 Apr 1. doi: 10.1111/dom.15560.
PMID: 38558508